Welcome to our dedicated page for Bridgebio Pharma news (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on Bridgebio Pharma stock.
BridgeBio Pharma, Inc. develops and commercializes medicines for genetic conditions through a decentralized biopharmaceutical model. News for BBIO centers on Attruby/acoramidis, its oral transthyretin stabilizer for transthyretin amyloid cardiomyopathy (ATTR-CM), including clinical data from ATTRibute-CM, commercial updates, Brazil marketing authorization under the BEYONTTRA name, and licensing or commercialization arrangements.
Company updates also cover late-stage genetic-disease programs such as encaleret for autosomal dominant hypocalcemia type 1, BBP-418 for limb-girdle muscular dystrophy type 2I/R9, and oral infigratinib for achondroplasia. Recurring financial and corporate items include quarterly results, product revenue trends, capital actions, employee equity inducement grants, investor conference participation, and pipeline regulatory disclosures.
BridgeBio (Nasdaq: BBIO) launched a national health-education campaign, Don’t Pass On Your Heart Health, to raise awareness of ATTR-CM and encourage earlier diagnosis and care among adults over 55.
The effort features Morgan Freeman and Howard “H” White, highlights findings from the Phase 3 ATTRibute-CM study showing treatment benefits with Attruby, and provides resources at Attruby.com.
BridgeBio Pharma (Nasdaq: BBIO) announced inducement equity grants approved April 18, 2026, for 33 new employees totaling 67,247 restricted stock units.
Vesting: 25% vests on May 16, 2027, then one‑twelfth of the remainder quarterly thereafter, subject to continued employment. Awards were granted under the company’s plan adopted November 2019 and amended February 10, 2023 and December 13, 2023.
BridgeBio (Nasdaq: BBIO) presented long-term data showing acoramidis provides sustained benefit through Month 54 in ATTR-CM. Continuous treatment reduced all-cause mortality by 44.7% and cardiovascular mortality by 49.3% (both p<0.0001) versus placebo-to-acoramidis.
Acoramidis mitigated NT-proBNP rise, stabilized KCCQ-OS heart-failure scores, was well tolerated long term, and is approved in the U.S., EU, Japan, Switzerland and the UK.
BridgeBio (Nasdaq: BBIO) submitted a New Drug Application to the FDA for oral BBP-418 to treat limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) on March 30, 2026.
The NDA includes interim Phase 3 FORTIFY data showing statistically significant, clinically meaningful improvements in ambulation and pulmonary function and a favorable safety profile. BridgeBio anticipates U.S. approval and a launch in late 2026/early 2027, is seeking expedited paths in Europe, and notes prior Orphan Drug, Fast Track, and Rare Pediatric designations.
BridgeBio (NASDAQ: BBIO) will present long-term efficacy and safety data from the ATTRibute-CM open-label extension (OLE) trial of acoramidis at the American College of Cardiology Annual Scientific Sessions in New Orleans on March 28-30, 2026.
A late-breaking oral presentation on survival and disease stabilization is scheduled for March 30 at 2:33 pm CT, plus three posters on biomarker, health-status and real-world survey findings on March 28 and March 30.
BridgeBio Pharma (Nasdaq: BBIO) announced inducement equity awards approved March 18, 2026 for 29 new employees totaling 70,916 restricted stock units.
One-fourth of each award vests on February 16, 2027, then one-twelfth of the remainder vests quarterly thereafter, subject to continued employment. Awards were granted under the company Plan adopted November 2019 and amended February 10, 2023 and December 13, 2023, pursuant to Nasdaq Listing Rule 5635(c)(4).
BridgeBio (Nasdaq: BBIO) presented positive Phase 3 FORTIFY interim data for oral BBP-418 in LGMD2I/R9 showing rapid, consistent efficacy and a favorable safety profile.
Key results: 31-second 100MTT benefit at 12 months, CK reductions with 38.3% normalization, comparable serious adverse event rates, and an intended NDA submission in H1 2026.
BridgeBio (Nasdaq: BBIO) will present additional interim Phase 3 FORTIFY data for BBP-418 in LGMD2I/R9 at the MDA Clinical & Scientific Conference in Orlando, March 8-11, 2026. A late-breaking oral presentation on March 11 will report the interim analysis meeting efficacy endpoints; collaborators will deliver one oral talk and four posters.
BridgeBio (Nasdaq: BBIO) reported $154.2M in Q4 2025 revenue and $502.1M for full-year 2025, driven mainly by Attruby net product sales of $146.0M (Q4) and $362.4M (FY). The company announced three positive Phase 3 readouts and plans multiple NDAs in 1H/2H 2026 with U.S. launches anticipated in late 2026/early 2027. Cash, equivalents, and marketable securities totaled $587.5M at year-end; BridgeBio completed issuance of $632.5M 2033 convertible notes in Jan 2026 to support commercial and pipeline operations.
BridgeBio (Nasdaq: BBIO) announced that management will participate in three March 2026 healthcare investor conferences with scheduled fireside chats in Boston and Miami.
Presentations include TD Cowen on March 2, 2026 at 3:50 pm ET, Leerink Partners on March 10, 2026 at 1:00 pm ET, and Barclays on March 11, 2026 at 12:30 pm ET. Live webcasts and 90-day replays will be available on the company website.